Nafamostat Mesylate CAS: 82956-11-4

Product Parameters
Catalog No. BA77H1
CAS.RN 82956-11-4
Molecular Formula C21H25N5O8S2
Molecular Weight 539.58 g/mol
Purity NLT 98%
Product Overview

Nafamostat Mesylate (CAS 82956-11-4) is an API product that may be used in pharmaceutical R&D, intermediate synthesis, process development, and quality research. Specific applications, specifications, and suitability should be confirmed according to project requirements.

Quality & Supply Capability

English Name : Nafamostat Mesylate

Supply Capability : Samples, gram scale, kilogram scale, and commercial batches

Packaging : Foil bags, fluorinated bottles, fiber drums, and custom packaging

Document Support : COA, MSDS, HPLC/GC, NMR, and other documents

Bioncan can provide sample supply, lab-scale preparation, pilot scale-up, and customized batch production for Nafamostat Mesylate (CAS 82956-11-4) according to customer project requirements. We can offer flexible supply plans based on purity, impurity control, packaging, delivery schedule, and quality documentation requirements. For Raw Materials and related projects, we provide technical support from laboratory research to scale-up production to help customers advance process development, route optimization, and project transfer.

Why Choose Bioncan

Bioncan is a manufacturer and supplier of Raw Materials-related products, with support for an API product. For Nafamostat Mesylate (CAS 82956-11-4), we can support sample requests, bulk production supply, custom synthesis communication, route optimization, specification confirmation, and project scale-up.

Products are offered for research, development, or industrial use only.
Customers are responsible for ensuring compliance with applicable patent, regulatory, and import/export requirements in their respective jurisdictions.
Online Consulting

For quotation, inventory, samples, COA, MSDS, or custom synthesis support for CAS 82956-11-4, please submit your requirements. We will respond according to purity, quantity, delivery timeline, and documentation needs.